Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 vaccine attitudes among mental health professionals in the WHO's global clinical practice network.

PLOS mental health·2026
Same author

The Use of VMAT2 Inhibitors for Tardive Dyskinesia.

Journal of clinical psychopharmacology·2026
Same author

Comparative Effectiveness Trials and the Quest for Personalized Treatments: The Case of Antipsychotics.

The American journal of psychiatry·2026
Same author

Machine learning for novel phenotyping in schizophrenia.

Schizophrenia research·2025
Same author

Mental disorders and criminal legal involvement: Evidence from a national diagnostic epidemiological survey.

PLOS mental health·2025
Same author

Neighborhood Social Vulnerability and Racial Disparities in Schizophrenia Spectrum Disorder Prevalence.

The American journal of psychiatry·2025
Same journal

Neuroimaging in older-age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Repetitive transcranial magnetic stimulation treatment for obsessive-compulsive disorder.

Current opinion in psychiatry·2026
Same journal

Pharmacological maintenance treatment in older age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Harmful behaviours and suicide in later life bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Urbanization, wildfire exposure, and youth mental health: a narrative review.

Current opinion in psychiatry·2026
Same journal

Bipolar disorder and the risk of developing dementia - a systematic review and meta-analysis.

Current opinion in psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Polypharmacy for schizophrenia.

Jacob Ballon1, T Scott Stroup

  • 1Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, USA.

Current Opinion in Psychiatry
|January 16, 2013
PubMed
Summary
This summary is machine-generated.

Psychiatric polypharmacy for schizophrenia is common but lacks robust evidence. While some combinations show potential benefits, such as antidepressants reducing mortality, more research is urgently needed to guide effective treatment.

More Related Videos

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Related Experiment Videos

Last Updated: May 15, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Psychotropic medication combining, or polypharmacy, is a frequent strategy for managing schizophrenia.
  • Individuals with schizophrenia often present with complex clinical needs necessitating multifaceted treatment approaches.

Purpose of the Study:

  • To provide an updated review of the scientific evidence concerning the efficacy of polypharmacy strategies in schizophrenia treatment.
  • To highlight the current state of research on combining different psychotropic medications for schizophrenia.

Main Methods:

  • Systematic review of existing literature.
  • Analysis of evidence from randomized controlled trials (RCTs) and observational studies.

Main Results:

  • Polypharmacy is highly prevalent in schizophrenia, yet robust evidence from RCTs supporting most combinations is scarce.
  • Antipsychotic combinations lack strong evidential support. Antidepressants, while commonly used for depressive symptoms, have limited RCT backing but may correlate with reduced mortality.
  • Evidence for benzodiazepine use in schizophrenia is insufficient, and observational studies suggest potential increased mortality risks, necessitating caution.

Conclusions:

  • The scarcity of evidence for common polypharmacy strategies complicates optimal pharmacotherapy for schizophrenia patients.
  • There is a critical need for comparative effectiveness research, utilizing both RCTs and observational methods, to inform clinical practice, optimize resource allocation, and improve patient outcomes.